Investigator

Kátia Luz Torres

Diretora de Ensino e Pesquisa · Centro de Controle de Oncologia do Estado do Amazonas, Diretoria de Ensino e Pesquisa

KLTKátia Luz Torres
Papers(2)
Moving towards a stra…The Role of cf-HPV DN…
Collaborators(6)
Mikele P. de OliveiraSandro MartinsValquíria C. A. Marti…Flávia Níniver O. Gom…Heidy Halanna de Melo…Higino F. Figueiredo
Institutions(4)
Universidade Do Estad…UniNorteUniversity Hospital o…Unknown Institution

Papers

Moving towards a strategy to accelerate cervical cancer elimination in a high-burden city—Lessons learned from the Amazon city of Manaus, Brazil

The World Health Organization Call to Eliminate Cervical Cancer resonates in cities like Manaus, Brazil, where the burden is among the world’s highest. Manaus has offered free cytology-based screening since 1990 and HPV immunization since 2013, but the public system is constrained by many challenges and performance is not well-defined. We obtained cervical cancer prevention activities within Manaus public health records for 2019 to evaluate immunization and screening coverage, screening by region and neighborhood, and the annual Pink October screening campaign. We estimated that among girls and boys age 14–18, 85.9% and 64.9% had 1+ doses of HPV vaccine, higher than rates for age 9–13 (73.4% and 43.3%, respectively). Of the 90,209 cytology tests performed, 24.9% were outside the target age and the remaining 72,230 corresponded to 40.1% of the target population (one-third of women age 25–64). The East zone had highest screening coverage (49.1%), highest high-grade cytology rate (2.5%) and lowest estimated cancers (38.1/100,000) compared with the South zone (32.9%, 1.8% and 48.5/100,000, respectively). Largest neighborhoods had fewer per capita screening locations, resulting in lower coverage. During October, some clinics successfully achieved higher screening volumes and high-grade cytology rates (up to 15.4%). Although we found evidence of some follow-up within 10 months post-screening for 51/70 women (72.9%) with high-grade or worse cytology, only 18 had complete work-up confirmed. Manaus has successfully initiated HPV vaccination, forecasting substantial cervical cancer reductions by 2050. With concerted efforts during campaigns, some clinics improved screening coverage and reached high-risk women. Screening campaigns in community locations in high-risk neighborhoods using self-collected HPV testing can achieve widespread coverage. Simplifying triage and treatment with fewer visits closer to communities would greatly improve follow-up and program effectiveness. Achieving WHO Cervical Cancer Elimination goals in high-burden cities will require major reforms for screening and simpler follow-up and treatment.

The Role of cf-HPV DNA as an Innovative Biomarker for Predicting the Recurrence or Persistence of Cervical Cancer

Background: Cervical cancer is highly prevalent among women in Amazonas, Brazil, mainly due to low screening coverage, and is diagnosed at a late stage, which compromises the treatment efficacy and survival rates. After treatment, recurrence is frequent, and there are few follow-up options to detect it. This highlights the urgent need for less-invasive biomarkers to monitor affected patients. Methods: This study employed real-time PCR, targeting the E7 gene of HPV types 16 and 18 to analyze cell-free DNA from plasma samples from 39 cervical cancer patients treated at the Oncology Control Center Foundation in Amazonas, Brazil. Results: cf-HPV 16 DNA was detected in 54% of the samples before treatment. The socioeconomic and behavioral data showed that 46.2% of the patients had low educational levels, 77% reported having a low income, 79.5% experienced an early sexual activity onset, and 15.4% had never undergone cytological screening. Persistence or recurrence occurred in 30.8% of cases over 4–33 months of follow-up, with cf-HPV DNA detectable in 75% of these cases. Conclusions: cf-HPV DNA in plasma is a promising biomarker for post-treatment surveillance, facilitating the earlier detection of persistence/recurrence. Incorporating this biomarker into clinical protocols could enhance outcomes and survival, particularly in underserved regions like the Amazon, where the access to healthcare is limited.

27Works
2Papers
6Collaborators

Positions

2011–

Diretora de Ensino e Pesquisa

Centro de Controle de Oncologia do Estado do Amazonas · Diretoria de Ensino e Pesquisa

Education

2009

Doctor Degree

Universidade de São Paulo · Doenças Infecciosas e Parasitárias

1999

Master Degree

Fundação Oswaldo Cruz · Doenças Infecciosas e Parasitária

1993

Graduation

Universidade Federal do Amazonas · Faculdade de Ciências farmaceuticas

Country

BR

Links & IDs
0000-0003-0922-5866

Scopus: 10042404800